Effects of Insulin Glargine vs Thiazolidinediones (TZDs) on Glycemic and Lipid Variables in T2DM

被引：0
|
作者：
Hollander, Priscilla
Rosenberg, Noah
Chaudhuri, Ajay
Nesto, Richard W.
Rosenstock, Julio
Meneghini, Luigi F.
Dandona, Paresh
Riddle, Matthew C.
机构：
来源：
DIABETES | 2009年 / 58卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A522 / A522
页数：1
相关论文
共 50 条
  • [41] Cognitive Effects of Intranasal Insulin in Older T2DM Adults
    Monti, Sara M.
    Galica, Andrew
    Novak, Peter
    Munshi, Medha
    Abduljalil, Amir
    Roberson, Paula K.
    Manor, Brad
    Milberg, William
    Novak, Vera
    [J]. DIABETES, 2013, 62 : A250 - A250
  • [42] Accelerated Insulin PK and Improved Glycemic Control in T2DM Patients by Coinjection of Prandial Insulin with Hyaluronidase
    Hompesch, Marcus
    Muchmore, Douglas
    Morrow, Linda
    Ludington, Elizabeth
    Vaughn, Daniel
    [J]. DIABETES, 2010, 59 : A103 - A103
  • [43] New Insulin Glargine 300 U/mL: Efficacy and Safety of Adaptable vs. Fixed Dosing Intervals in People with T2DM
    Riddle, Matthew C.
    Bolli, Geremia B.
    Home, Phillip D.
    Bergenstal, Richard
    Ziemen, Monika
    Muehlen-Bartmer, Isabel
    Wardecki, Marek
    Vinet, Laetitia
    Yki-Jarvinen, Hannele
    [J]. DIABETES, 2014, 63 : A235 - A235
  • [44] Effect of pioglitazone on vascular reactivity is associated with improved insulin resistance and lipid metabolism, but not glycemic control, in Mexican Americans with T2DM
    Wajcberg, Estela
    Fernandez, Marianella
    Defronzo, Ralph A.
    Cersosimo, Eugenio
    [J]. DIABETES, 2006, 55 : A145 - A146
  • [45] Association of Fasting C-Peptide Levels with Glycemic Efficacy and Risk of Hypoglycemia in People with T2DM Commencing Insulin Glargine 100 U/mL
    Owens, David R.
    Landgraf, Wolfgang
    Zhang, Mei
    Traylor, Louise
    Frier, Brian M.
    Bolli, Geremia B.
    Home, Philip D.
    [J]. DIABETES, 2017, 66 : A264 - A264
  • [46] Meta-analysis of Clinical Outcomes According to Age in T2DM Patients Initiating Insulin Glargine
    Haak, Thomas J.
    Traylor, Louise
    Landgraf, Wolfgang
    Owens, David R.
    [J]. DIABETES, 2015, 64 : A256 - A257
  • [47] Impact of baseline gastric emptying on effects of lixisenatide and liraglutide in type 2 diabetes mellitus (T2DM) as add-on to insulin glargine
    Menge, B. A.
    Kapitza, C.
    Hincelin-Mery, A.
    Roy-Duval, C.
    Delfolie, A.
    Coester, H. -V.
    Forst, T.
    Meier, J. J.
    [J]. DIABETOLOGIA, 2014, 57 : S38 - S38
  • [48] INSILICO STUDY EXAMINING INITIATION OF INSULIN GLARGINE U100 IN VIRTUAL SUBJECTS WITH T2DM
    Sieber, J.
    Weinheimer, M.
    Kongable, G.
    Riddle, S.
    Chang, Y. Y.
    Flacke, F.
    [J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2018, 20 : A82 - A82
  • [49] Physician beliefs in efficacy of insulin glargine (GLAR) are associated with glucose control in type 2 diabetes (T2DM)
    Herman, W.
    Zhang, Q.
    Kennedy, L.
    [J]. DIABETOLOGIA, 2006, 49 : 527 - 528
  • [50] Benefits of a Fixed-Ratio Formulation of Once-Daily Insulin Glargine/Lixisenatide (LixiLan) vs. Glargine in Type 2 Diabetes (T2DM) Inadequately Controlled on Metformin
    Rosenstock, Julio
    Diamant, Michaela
    Silvestre, Louise
    Souhami, Elisabeth
    Zhou, Tianyue
    Fonseca, Vivian
    [J]. DIABETES, 2014, 63 : A87 - A88
12345